Given the likelihood that insufficient numbers of patients will be available for a randomized controlled trial of MAOIs in refractory depression or atypical depression, we must still rely on consensus guidelines and expert opinion.
Scott E. Walker, MScPhm
Advertisement
Articles by Scott E. Walker, MScPhm
Advertisement
Latest Updated Articles
Irreversible Monoamine Oxidase Inhibitors RevisitedPublished: October 8th 2012 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lithium-Loaded Gold Nanoparticle Nasal Spray to Treat Neuropsychiatric Diseases
2
Preliminary Report on Dangers of AI Chatbots
3
The Trial of ChatGPT: What Psychiatrists Need to Know About AI, Suicide, and the Law
4
LSD for Generalized Anxiety Disorder: New Findings Review With Maurizio Fava, MD
5
